{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:45Z","timestamp":1792684005550,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"abstract":"<jats:sec id=\"ab-eoi260061-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>A confirmed visual field progression event in glaucoma typically prompts intensification of intraocular pressure (IOP)\u2013lowering therapy, yet the factors associated with recurrent progression after that first event remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260061-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the incidence of recurrent visual field progression after an initial Guided Progression Analysis (GPA) likely-progression event and the factors associated with a recurrent event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260061-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study was conducted among patients receiving routine ophthalmic care between 1998 and 2025 at a single tertiary academic center (Bascom Palmer Ophthalmic Registry). Data were analyzed from February 2026 to August 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260061-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes were the cumulative probability of recurrent visual field progression and hazard ratios (HRs) for factors associated with recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260061-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 7457 eyes of 5086 patients with open-angle glaucoma or suspected glaucoma were included, with a mean (SD) follow-up of 12.4 (4.6) years. Mean (SD) patient age was 60.5 (13.1) years, and 4468 eyes (59.9%) were from female patients. By self-reported race and ethnicity, 203 eyes (2.7%) were from Asian patients, 1718 (23.0%) from Black patients, 1677 (22.5%) from Hispanic patients, and 5536 (74.2%) from White patients. A total of 1951 eyes (26.2%) developed initial GPA likely progression; 635 eyes had adequate follow-up after first progression and IOP data. Among those, 167 (26.3%) recurred. Kaplan-Meier cumulative recurrence was 13.8% at 3 years (95% CI, 11.6%-17.1%) and 43.5% at 10 years (95% CI, 35.8%-52.1%). In multivariable Cox analysis, faster mean deviation (MD) loss before first progression (HR, 1.73 per 1 decibel [dB]\/y; 95% CI, 1.39-2.15), higher mean IOP after the first event (HR, 1.09 per 1 mm Hg; 95% CI, 1.05-1.13), less negative MD at first progression (HR, 1.08 per 1 dB; 95% CI, 1.04-1.12), and older age (HR, 1.11 per 5 years; 95% CI, 1.03-1.19) were independently associated with recurrence. Each 10% greater IOP reduction was associated with lower hazard (HR, 0.89; 95% CI, 0.83-0.94). Among eyes with pre-event MD slopes faster than \u22121.0 dB\/y, recurrence occurred in 42.7% of eyes vs 23.4% in slower-progressing eyes (difference, 19.3%; 95% CI, 8.8%-29.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260061-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Findings from this cohort study suggest that recurrent visual field progression after a first GPA progression event is common; eyes at highest risk had faster pre-event visual field loss, less advanced damage at first progression, higher postevent IOP, and older age. These results may help target intensified monitoring and IOP lowering toward higher-risk eyes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.4609","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:47Z","timestamp":1792683047000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Risk Factors of Recurrent Visual Field Progression in Glaucoma"],"prefix":"10.1001","author":[{"given":"Davina A.","family":"Malek","sequence":"first","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"da Costa","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Scherer","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"10","key":"eoi260061r1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"9975","key":"eoi260061r2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"eoi260061r3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration.","volume":"130","author":"The AGIS Investigators","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi260061r4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma.","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi260061r5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"eoi260061r6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"eoi260061r7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2008.08.051","article-title":"Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors.","volume":"116","author":"Musch","year":"2009","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi260061r8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","article-title":"Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.","volume":"126","author":"Chauhan","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"eoi260061r9","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.ophtha.2009.06.042","article-title":"Natural history of open-angle glaucoma.","volume":"116","author":"Heijl","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi260061r10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archophthalmol.2011.72","article-title":"Risk factors for visual field progression in treated glaucoma.","volume":"129","author":"De Moraes","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"eoi260061r11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0161-6420(97)30192-4","article-title":"Estimating progression of visual field loss in glaucoma.","volume":"104","author":"Katz","year":"1997","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi260061r12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajo.2007.09.038","article-title":"A visual field index for calculation of glaucoma rate of progression.","volume":"145","author":"Bengtsson","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi260061r13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ophtha.2011.08.041","article-title":"Glaucoma Progression Analysis software compared with expert consensus opinion in the detection of visual field progression in glaucoma.","volume":"119","author":"Tanna","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi260061r14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/eye.2013.77","article-title":"Agreement between event-based and trend-based glaucoma progression analyses.","volume":"27","author":"Rao","year":"2013","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi260061r15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5301\/ejo.5000193","article-title":"Glaucoma progression detection: agreement, sensitivity, and specificity of expert visual field evaluation, event analysis, and trend analysis.","volume":"23","author":"Ant\u00f3n","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"eoi260061r16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ophtha.2011.10.003","article-title":"Integrating event- and trend-based analyses to improve detection of glaucomatous visual field progression.","volume":"119","author":"Medeiros","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi260061r17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.survophthal.2020.04.004","article-title":"Functional assessment of glaucoma: uncovering progression.","volume":"65","author":"Hu","year":"2020","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"eoi260061r18","doi-asserted-by":"publisher","first-page":"16353","DOI":"10.1038\/s41598-021-95877-9","article-title":"Improving event-based progression analysis in glaucomatous visual fields.","volume":"11","author":"Rui","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"eoi260061r19","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.ophtha.2014.04.015","article-title":"Visual field progression in glaucoma: what is the specificity of the Guided Progression Analysis?","volume":"121","author":"Artes","year":"2014","journal-title":"Ophthalmology"},{"key":"eoi260061r20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ajo.2020.05.019","article-title":"Rates of glaucomatous structural and functional change from a large clinical population: the Duke Glaucoma Registry study.","volume":"222","author":"Jammal","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi260061r21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/IJG.0000000000001985","article-title":"Evaluating visual field progression in advanced glaucoma using trend analysis of targeted mean total deviation.","volume":"31","author":"Miki","year":"2022","journal-title":"J Glaucoma"},{"issue":"4","key":"eoi260061r22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1167\/tvst.7.4.20","article-title":"Comparison of visual field point-wise event-based and global trend-based analysis for detecting glaucoma progression.","volume":"7","author":"Wu","year":"2018","journal-title":"Transl Vis Sci Technol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2855442\/jamaophthalmology_malek_2026_oi_260061_1791572860.50291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:48Z","timestamp":1792683048000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2855442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.4609","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,22]]}}}